SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 148.1% in November

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 99,000 shares, an increase of 148.1% from the November 15th total of 39,900 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 90,700 shares, the short-interest ratio is presently 1.1 days.

SAB Biotherapeutics Stock Up 5.4 %

NASDAQ:SABS traded up $0.21 during midday trading on Friday, reaching $4.08. 31,140 shares of the stock traded hands, compared to its average volume of 35,255. SAB Biotherapeutics has a 12 month low of $2.16 and a 12 month high of $8.40. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $3.14 and a 200 day moving average of $2.92.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, equities research analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC bought a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 7.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SABS shares. Chardan Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Oppenheimer reaffirmed an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Finally, Craig Hallum assumed coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.